JP2010524952A5 - - Google Patents

Download PDF

Info

Publication number
JP2010524952A5
JP2010524952A5 JP2010504191A JP2010504191A JP2010524952A5 JP 2010524952 A5 JP2010524952 A5 JP 2010524952A5 JP 2010504191 A JP2010504191 A JP 2010504191A JP 2010504191 A JP2010504191 A JP 2010504191A JP 2010524952 A5 JP2010524952 A5 JP 2010524952A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
alkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010504191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010524952A (ja
JP5635398B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/060366 external-priority patent/WO2008128231A1/en
Publication of JP2010524952A publication Critical patent/JP2010524952A/ja
Publication of JP2010524952A5 publication Critical patent/JP2010524952A5/ja
Application granted granted Critical
Publication of JP5635398B2 publication Critical patent/JP5635398B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010504191A 2007-04-16 2008-04-15 ピリミジン誘導体 Expired - Fee Related JP5635398B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91192107P 2007-04-16 2007-04-16
US60/911,921 2007-04-16
PCT/US2008/060366 WO2008128231A1 (en) 2007-04-16 2008-04-15 Pyrimidine derivatives

Publications (3)

Publication Number Publication Date
JP2010524952A JP2010524952A (ja) 2010-07-22
JP2010524952A5 true JP2010524952A5 (enExample) 2011-06-02
JP5635398B2 JP5635398B2 (ja) 2014-12-03

Family

ID=39854302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504191A Expired - Fee Related JP5635398B2 (ja) 2007-04-16 2008-04-15 ピリミジン誘導体

Country Status (17)

Country Link
US (2) US8349859B2 (enExample)
EP (1) EP2154967B9 (enExample)
JP (1) JP5635398B2 (enExample)
KR (1) KR101424847B1 (enExample)
BR (1) BRPI0809715A2 (enExample)
CA (1) CA2684470C (enExample)
DK (1) DK2154967T5 (enExample)
ES (1) ES2465673T3 (enExample)
HR (1) HRP20140377T2 (enExample)
MX (1) MX2009011199A (enExample)
NZ (1) NZ580671A (enExample)
PL (1) PL2154967T3 (enExample)
PT (1) PT2154967E (enExample)
RU (1) RU2455994C2 (enExample)
SI (1) SI2154967T1 (enExample)
TW (1) TWI484960B (enExample)
WO (1) WO2008128231A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
AR074210A1 (es) * 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ttk阻害作用を有するピリジンおよびピリミジン誘導体
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
CN102070618B (zh) * 2009-11-23 2013-08-21 和记黄埔医药(上海)有限公司 一种化合物及其晶体
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
EP2395001A1 (en) 2010-05-21 2011-12-14 Chemilia AB Novel pyrimidine derivatives
EP2433636A1 (en) * 2010-09-27 2012-03-28 Medizinische Universität Wien Treatment of Malignant Diseases
WO2012044561A2 (en) * 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. 2-alkoxy pyrimidine pde10 inhibitors
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
EP2502924A1 (en) 2011-03-24 2012-09-26 Chemilia AB Novel pyrimidine derivatives
WO2013054351A1 (en) * 2011-08-08 2013-04-18 Cadila Healthcare Limited Heterocyclic compounds
EP2711365A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
CA2890018A1 (en) 2012-11-05 2014-05-08 Nant Holdings Ip, Llc Substituted indol-5-ol derivatives and their therapeutical applications
RU2015143657A (ru) * 2013-03-15 2017-04-27 Нэнтбайосайенс, Инк. Замещенные производные индол-5-ола и их терапевтические применения
CN105601573B (zh) * 2014-11-24 2021-07-02 中国科学院上海药物研究所 2-氨基嘧啶类化合物及其药物组合物和应用
EP3261637B1 (en) * 2015-02-27 2021-05-26 NantBioScience, Inc. Pyrimidine derivatives as kinase inhibitors and their therapeutical applications
US10981899B2 (en) 2016-04-28 2021-04-20 Cornell University Inhibitors of soluble adenylyl cyclase
CN112513029B (zh) * 2019-06-21 2023-10-24 上海翰森生物医药科技有限公司 含氮芳基磷氧化物类衍生物、其制备方法和应用
CN111004221B (zh) * 2019-12-13 2021-02-02 长治学院 一种嘧啶/苯并咪唑杂合物、制备方法及医药用途
EP4251613A4 (en) * 2020-11-27 2024-11-20 Allorion Therapeutics Inc. AMINOHETEROARYL KINASE INHIBITORS

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
US6235741B1 (en) * 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US6943161B2 (en) * 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
AU3704101A (en) * 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU2001277621A1 (en) * 2000-08-09 2002-03-04 Astrazeneca Ab Antiangiogenic bicyclic derivatives
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
BR0116452A (pt) * 2000-12-21 2003-09-30 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto
HUP0400606A2 (hu) * 2001-03-01 2004-12-28 Ono Pharmaceutical Co., Ltd. 2-Metil-indol-4-ecetsav és intermedierei és eljárás előállításukra
US20040171630A1 (en) * 2001-06-19 2004-09-02 Yuntae Kim Tyrosine kinase inhibitors
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003220970A1 (en) 2002-03-01 2003-09-16 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
CA2489648A1 (en) 2002-06-17 2003-12-24 Smithkline Beecham Corporation Chemical process
HRP20050089B1 (hr) * 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
US20060004029A1 (en) * 2002-08-30 2006-01-05 Akihiko Tsuruoka Nitrogen-containing aromatic derivatives
US7189712B2 (en) 2002-10-10 2007-03-13 Smithkline Beecham Corporation 1,3-Oxazole compounds for the treatment of cancer
JP2006508997A (ja) 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Chk−、Pdk−およびAkt−阻害性ピリミジン、それらの製造および薬剤としての使用
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
US8084457B2 (en) * 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
US20070105839A1 (en) * 2003-09-18 2007-05-10 Patricia Imbach 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
EP1684762A4 (en) * 2003-11-13 2009-06-17 Ambit Biosciences Corp UREA DERIVATIVES AS MODULATORS OF KINASE
US7718697B2 (en) 2003-12-17 2010-05-18 Alcon, Inc. Method for treating glaucoma comprising administering α-lipoic acid
AU2004309166B2 (en) 2003-12-23 2008-02-21 Pfizer Inc. Novel quinoline derivatives
DE102004044556A1 (de) * 2004-09-15 2006-03-30 Bayer Healthcare Ag Behandlung viraler Infektionen durch selektive Zerstörung virusinfizierter Zellen mit Stresskinase-Inhibitoren
TW200628463A (en) * 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
US7851466B2 (en) * 2004-11-19 2010-12-14 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
WO2006071079A1 (en) 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
US20060247263A1 (en) * 2005-04-19 2006-11-02 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1883302A4 (en) * 2005-05-03 2009-05-20 Rigel Pharmaceuticals Inc JAK KINASE HEMMER AND ITS USE
NZ564222A (en) 2005-06-14 2011-10-28 Taigen Biotechnology Co Ltd Pyrimidine compounds
US20090149467A1 (en) * 2005-09-15 2009-06-11 Merck & Co., Inc. Tyrosine Kinase Inhibitors

Similar Documents

Publication Publication Date Title
JP2010524952A5 (enExample)
JP2012041349A5 (enExample)
JP2011526913A5 (ja) キナゾリン化合物及び同化合物を含む治療薬
JP2011519956A5 (ja) キナゾリン誘導体及び同キナゾリン誘導体を含む治療薬
JP2013537203A5 (enExample)
JP2015508749A5 (enExample)
HRP20140377T2 (hr) Derivati pirimidina
JP2017526677A5 (enExample)
JP2016503797A5 (enExample)
BRPI0714315B8 (pt) arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende
JP2012516871A5 (enExample)
BRPI0820112B8 (pt) derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento
JP2018502912A5 (enExample)
JP2016505614A5 (enExample)
JP2014512364A5 (enExample)
JP2013530176A5 (enExample)
JP2011504903A5 (enExample)
JP2016534134A5 (enExample)
JP2011509949A5 (enExample)
JP2009523760A5 (enExample)
JP2009536620A5 (enExample)
JP2016505637A5 (enExample)
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
JP2017504635A5 (enExample)
RU2016151420A (ru) Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий